FindTrial
Sign In

Efbemalenograstim alfa Injection

DRUG2 trials

Sponsors

Shandong Cancer Hospital and Institute, Henan Cancer Hospital

Conditions

Chemotherapy Induced NeutropeniaG-CSFHigh Risk for Febrile Neutropenia of Chemotherapy RegimensIntermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile NeutropeniaPrimary/Secondary PreventionSolid Tumor Cancer

Phase 2

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
RecruitingNCT07187908
Henan Cancer HospitalHigh Risk for Febrile Neutropenia of Chemotherapy Regimens, Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia, Primary/Secondary Prevention
Start: 2025-01-01End: 2027-10-31Target: 1076Updated: 2025-09-23

Unknown Phase

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.
Not yet recruitingNCT06649448
Shandong Cancer Hospital and InstituteChemotherapy Induced Neutropenia, G-CSF, Solid Tumor Cancer
Start: 2024-10-10End: 2026-05-31Target: 200Updated: 2024-10-18